Eli Lilly expands pain management portfolio with acquisition

18 January 2017

Eli Lilly (NYSE: LLY) has announced plans to enhance its existing portfolio in pain management for migraine, while adding a potential near-term launch to its late-stage pipeline.

The US pharma major says it has reached an agreement to acquire CoLucid Pharmaceuticals (Nasdaq: CLCD) for $46.50 per share - a 33% premium to the stock’s closing price on Tuesday - or around $960 million. CoLucid shares leapt 32.7% to $46.30 in pre-market trading today.

The transaction is expected to close by the end of the first quarter of 2017, subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical